LobbyingNobelpharma America lobbying by quarter
Nobelpharma America's latest lobbying report covers Q2 2026, at under $5,000. Its first report covers Q4 2022; the issues it reports most are Health Issues.
Nobelpharma America
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $0
- Last 4 quarters
- vs last quarter
- No record
- Q3 2026 against the quarter before
- First report
- Q4 2022
- The first quarter a report named it
Lobbying by quarter
No lobbying spend in this period.
| Quarter | Amount | Reports |
|---|---|---|
| Q4 2022 | $0 | 1 |
| Q1 2023 | $0 | 1 |
| Q2 2023 | $0 | 1 |
| Q3 2023 | $0 | 1 |
| Q4 2023 | $0 | 1 |
| Q1 2024 | $0 | 1 |
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 1 |
| Q1 2025 | $0 | 1 |
| Q2 2025 | $0 | 1 |
| Q3 2025 | $0 | 1 |
| Q4 2025 | $0 | 1 |
| Q1 2026 | $0 | 1 |
| Q2 2026 | $0 | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$0 · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES2 reports
- SENATE2 reports
Firms it paid
| Firm | ||
|---|---|---|
| M.J. Simon & Company | $0 | 15 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARSHA SIMON | Senate Appropriations | Q1 2023 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | M.J. Simon & Company | Under $5,000 |
| 04/20for Q1 | M.J. Simon & Company | Under $5,000 |
| 01/20for Q4 2025 | M.J. Simon & Company | Under $5,000 |
| 25/10/20for Q3 2025 | M.J. Simon & Company | Under $5,000 |
| 25/08/05for Q2 2025 | M.J. Simon & Company | Under $5,000 |
| 25/04/17for Q1 2025 | M.J. Simon & Company | Under $5,000 |
| 25/01/17for Q4 2024 | M.J. Simon & Company | Under $5,000 |
| 24/10/21for Q3 2024 | M.J. Simon & Company | Under $5,000 |
| 24/08/13for Q2 2024 | M.J. Simon & Company | Under $5,000 |
| 24/04/19for Q1 2024 | M.J. Simon & Company | Under $5,000 |
| 24/01/18for Q4 2023 | M.J. Simon & Company | Under $5,000 |
| 23/10/20for Q3 2023 | M.J. Simon & Company | Under $5,000 |
| 23/07/19for Q2 2023 | M.J. Simon & Company | Under $5,000 |
| 23/04/21for Q1 2023 | M.J. Simon & Company | Under $5,000 |
| 23/01/20for Q4 2022 | M.J. Simon & Company | Under $5,000 |